ArticleDiscover nano2026
Antibacterial properties of polydopamine-modified ZnO nanoparticles composite films for oral therapeutic applications.
Article in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
In this work, a solvent evaporation casting approach was used to prepare ZnO@PDA/Zein nanocomposite films, where polydopamine-modified zinc oxide nanoparticles (ZnO@PDA NPs) were incorporated into a zein matrix as the film-forming agent. This nanocomposite film adhered uniformly to the surface of oral therapeutic instruments and exhibited good antibacterial effects. At a doping concentration of 1.2 mg/mL, the film exhibited an antibacterial effect against Gram-negative bacteria such as Escherichia coli (E. coli), and at a doping concentration of 0.6 mg/mL, the film exhibited antibacterial effects against Gram-positive bacteria such as Staphylococcus aureus (S. aureus) and Streptococcus mutans (S. mutans), along with good biocompatibility. This study introduces a novel ZnO@PDA/Zein nanocomposite film with enhanced antibacterial efficacy and biocompatibility, offering a promising solution for preventing biofilm formation on oral therapeutic instruments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.